Related Experiment Videos
Myeloperoxidase binds to low-density lipoprotein: potential implications for atherosclerosis
A C Carr1, M C Myzak, R Stocker
1Linus Pauling Institute, Oregon State University, 571 Weniger Hall, Corvallis, OR 97331-6512, USA. anitra.carr@orst.edu
FEBS Letters
|January 11, 2001
Summary
Myeloperoxidase (MPO) binds to low-density lipoprotein (LDL), potentially promoting atherosclerosis. This interaction may enhance LDL oxidation and hinder antioxidant activity, contributing to foam cell formation.
Area of Science:
- Biochemistry
- Cardiovascular Research
- Cell Biology
Background:
- Myeloperoxidase (MPO) is an enzyme released by phagocytes.
- MPO modifies low-density lipoprotein (LDL), leading to foam cell formation, a key feature of atherosclerosis.
- MPO's interaction with various cell types is known, but its binding to LDL was uninvestigated.
Purpose of the Study:
- To investigate the binding of Myeloperoxidase (MPO) to low-density lipoprotein (LDL).
- To understand the implications of MPO-LDL interaction in the context of atherosclerosis.
Main Methods:
- Co-precipitation of MPO and LDL using phosphotungstate or isopropanol.
- Confirmation of MPO-LDL association via native gel electrophoresis.
- Analysis of MPO precipitation with lipoproteins in whole plasma and lipoprotein-deficient plasma.
Main Results:
- MPO co-precipitated with LDL, retaining its catalytic activity.
- MPO associated with apolipoprotein B-100-containing lipoproteins in plasma.
- LDL addition to lipoprotein-deficient plasma showed a dose-dependent increase in MPO precipitation.
Conclusions:
- Myeloperoxidase (MPO) directly binds to low-density lipoprotein (LDL).
- This binding may enhance site-directed oxidation of LDL.
- The MPO-LDL interaction could potentially limit antioxidant scavenging of reactive oxygen species, promoting atherosclerotic lesion development.